WP
FNCH

WealthSource Partners’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

WealthSource Partners’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-600
Closed -$7.07K – 533
2023
Q1 		$7.07K Buy
600
+233
+63% +$3.09K ﹤0.01% 489
2022
Q4 		$5.28K Sell
367
-16
-4% -$535 ﹤0.01% 479
2022
Q3 		$19K Hold
383
– – ﹤0.01% 483
2022
Q2 		$33K Buy
+383
New +$32.8K ﹤0.01% 505

Other funds holding FNCH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

WealthSource Partners's FNCH Position: Q2 2023 in Review

WealthSource Partners sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 600 shares — an estimated $7.07K sold.

WealthSource Partners first reported a position in FNCH in Q2 2022 and held it in 4 quarters. The position peaked at $33K in Q2 2022. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

  • WealthSource Partners reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • WealthSource Partners sold 600 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $7.07K.
  • WealthSource Partners first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • WealthSource Partners's Finch Therapeutics Group, Inc. Common Stock position peaked at $33K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on WealthSource Partners's 13F filing for Q2 2023, filed 15 Aug 2023.